KAILERA THERAPEUTICS INC (KLRA)
NASDAQHealth CareBiotechnologySnapshot 2026-07-07
$22.24-4.55%
Close 2026-07-07 · 1-day change
Reading KLRA? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track KLRA free→NASDAQHealth CareBiotechnologySnapshot 2026-07-07
Reading KLRA? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track KLRA free→Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
KLRA's growth depends on positive clinical data and leadership changes to justify its price. Recent news shows strong clinical data supporting product development and a new corporate officer. KLRA trades at a premium with a 65% chance of missing earnings next quarter. If KLRA misses again, it could face continued pressure. Peer multiples imply a price about 12% below where it trades. This read is provisional.
Trailing returns as of 2026-07-07. KLRA is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 6 analysts currently covering KLRA (as of Jul 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A consensus fair price across 0 valuation methods, at three horizons. Current price $22.24. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
New leadership role may enhance corporate strategy.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-07. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Leadership change may improve strategic direction.
New appointment strengthens management team.
Positive clinical data supports product development.
Clinical data presentations enhance credibility.
Phase 2 trial success boosts product pipeline.
Initiation of Phase 3 trial indicates progress.
Positive data supports product development in obesity treatment.